The case for SABR as the global standard for non-operable early-stage non-small cell lung cancer-Reference-Cited by-同舟云学术

The case for SABR as the global standard for non-operable early-stage non-small cell lung cancer

Published:2022-10 Issue: Volume:14 Page:100361
ISSN:2667-193X
Container-title:The Lancet Regional Health - Americas
language:en
Short-container-title:The Lancet Regional Health - Americas

Author:

Mutsaers Adam,Louie Alexander V.,Ynoe Moraes Fabio^ORCID

Publisher

Elsevier BV

Reference11 articles.

1. Radiotherapy with curative intent in patients with early-stage, medically inoperable, non-small-cell lung cancer: a systematic review;Falkson;Clin Lung Cancer,2017

2. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial;Ball;The Lancet Oncol,2019

3. SPACE - a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC;Nyman;Radiother Oncol,2016

4. Cost-effectiveness of stereotactic body radiotherapy versus conventional radiotherapy for the treatment of surgically ineligible stage I non-small cell lung cancer in the Brazilian public health system;Arruda;Lancet Reg Health Ame,2022

5. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline;Videtic;Pract Radiat Oncol,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereotactic body radiotherapy for Ultra-Central lung Tumors: A systematic review and Meta-Analysis and International Stereotactic Radiosurgery Society practice guidelines;Lung Cancer;2023-08